| Comparison of Bevacizumab and Combined Low-dose Bevacizumab and Triamcinolone in Central Retinal Vein Occlusion. |
|
Byung Jae Kim, Hyun Woong Kim, Yong Seop Han, Jong Moon Park, In Young Chung |
1Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea. in0chung@hanmail.net
2Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
3Institute of Health Science, Gyeongsang National University, Jinju, Korea. |
| 중심망막정맥폐쇄에서 베바시주맙군과 저용량 베바시주맙-트리암시놀론 혼합군의 단기 효과 비교 |
|
김병재1⋅김현웅2⋅한용섭1,3⋅박종문1,3⋅정인영1,3 |
|
경상대학교 의학전문대학원 안과학교실1, 인제대학교 의과대학 부산백병원 안과학교실2, 경상대학교 건강과학연구원3 |
|
|
| Abstract |
PURPOSE
To report the effects and intraocular pressure (IOP) results of intravitreal injection of bevacizumab alone compared with intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection in patients with central retinal vein occlusion. METHODS: In total, 40 eyes of 40 patients diagnosed with central retinal vein occlusion were evaluated. Of these, 20 eyes of 20 patients were injected with intravitreal bevacizumab (1.25 mg/0.05 mL), and 20 eyes of 20 patients were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best corrected visual acuity (BCVA), central macular thickness (CMT), and IOP of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection. RESULTS: In both the intravitreal bevacizumab and the low-dose bevacizumab combined with low-dose triamcinolone groups, CMT decreased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). In addition, in both groups, neither IOP nor BCVA decreased significantly at 1 month, 2 months, or 3 months after injection (p > 0.05). The BCVA, IOP, and CMT at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05). CONCLUSIONS: The CMT of both groups decreased significantly, and BCVA of both groups increased significantly in patients with central retinal vein occlusion. Injection of low-dose intravitreal bevacizumab combined with low-dose intravitreal triamcinolone may be useful for the treatment of central retinal vein occlusion. |
| Key Words:
Central retinal vein occlusion;Intravitreal bevacizumab injection;Intravitreal triamcinolone injection |
|
PDF Links
Full text via DOI
Download Citation
